[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100624427":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":26,"centralContacts":31,"locations":37,"responsibleParty":51,"collaborators":53,"id":55,"slug":56,"hasResults":57,"nctId":58,"briefTitle":59,"officialTitle":59,"acronym":26,"eligibilityCriteria":60,"healthyVolunteers":57,"sex":61,"minAge":62,"maxAge":63,"enrollmentInfo":64,"targetDuration":26,"studyType":67,"phases":68,"briefSummary":70,"conditions":71,"keywords":75,"overallStatus":40,"whyStopped":26,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":88},{"fullName":5,"class":6},"Hanoi Medical University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"PPOS protocol","EXPERIMENTAL","FSH + Dydrogesterone 20mg\u002Fday from day 2 - 3 of the menstrual cycle. Optional LH supplementation. Freeze-all with time-lapse monitoring.",[13],"Drug: Progestin-Primed Ovarian Stimulation",{"label":15,"type":16,"description":17,"interventionNames":18},"Antagonist protocol","ACTIVE_COMPARATOR","FSH + Orgalutran 0.25 mg\u002Fday (starting when follicle ≥12 mm). Optional LH supplementation. Freeze-all with time-lapse monitoring.",[19],"Drug: Antagonist protocol for IVF",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Progestin-Primed Ovarian Stimulation","Ovarian stimulation using progestin-primed ovarian stimulation (PPOS) protocol. Patients receive recombinant FSH starting from day 2-3 of menstrual cycle, concomitantly with oral Dydrogesterone 20mg daily to prevent premature LH surge. All embryos are cultured using time-lapse technology and cryopreserved for subsequent frozen embryo transfer.",[9],null,{"type":22,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"Antagonist protocol for IVF","Ovarian stimulation using GnRH antagonist protocol. Patients receive recombinant FSH starting from day 2-3 of menstrual cycle. GnRH antagonist is added when leading follicle reaches 12-14mm diameter to prevent premature LH surge. All embryos are cultured using time-lapse technology and cryopreserved for subsequent frozen embryo transfer.",[15],[32],{"name":33,"role":34,"phone":35,"phoneExt":26,"email":36},"Thanh Huy Dao, MD","CONTACT","+84 971597096","huythanhdao.hmu@gmail.com",[38],{"facility":39,"status":40,"city":41,"state":26,"zip":42,"country":43,"countryCode":44,"cosmosGeoPoint":45,"geoPoint":50,"contacts":26},"Hanoi Obstetrics and Gynecology Hospital","RECRUITING","Hanoi","100000","Vietnam","VN",{"type":46,"coordinates":47},"Point",[48,49],105.84117,21.0245,{"lat":49,"lon":48},{"type":52,"investigatorFullName":26,"investigatorTitle":26,"investigatorAffiliation":26,"oldNameTitle":26,"oldOrganization":26},"SPONSOR",[54],{"name":39,"class":6},"100624427","ivf-outcomes-with-time-lapse-culture-comparison-between-ppos-and-gnrh-antagonist-protocols-100624427",false,"NCT07409493","IVF Outcomes With Time-Lapse Culture: Comparison Between PPOS and GnRH Antagonist Protocols","Inclusion Criteria:\n\n* Women aged 20-45 years\n* Indicated for in vitro fertilization (IVF) treatment\n* Planned freeze-all embryo strategy\n* Voluntary participation in research.\n\nExclusion Criteria:\n\n* Systemic diseases\n* Use of hormonal medications within 3 months prior to enrollment\n* Oocyte donation cycles\n* Unwilling or unable to participate in research","FEMALE","20 Years","45 Years",{"count":65,"type":66},148,"ESTIMATED","INTERVENTIONAL",[69],"NA","The goal of this clinical trial is to compare two ovarian stimulation protocols used in in vitro fertilization (IVF): the fixed Progestin-Primed Ovarian Stimulation (PPOS) protocol and the GnRH Antagonist protocol. The study will evaluate IVF outcomes and embryo development patterns using time-lapse embryo monitoring technology. The main questions the study aims to answer are:\n\n* Does the fixed - PPOS protocol achieve similar numbers of mature eggs, good-quality embryos, and clinical outcomes compared to the GnRH Antagonist protocol?\n* Are there differences in embryo development patterns (morphokinetics) between the two protocols when monitored by time-lapse imaging?\n* How does embryo quality (KIDScore) compare between the two protocols?\n\nStudy Design:\n\nResearchers will randomly assign 148 women undergoing IVF to two groups:\n\n* PPOS group (n=74): Will receive FSH injections (oral Duphaston 20mg daily) starting from day 2-3 of the menstrual cycle\n* GnRH Antagonist group (n=74): Will receive FSH injections (Orgalutran 0.25mg injections) when follicles reach ≥14mm\n\nParticipants will:\n\n* Undergo controlled ovarian stimulation with their assigned protocol for approximately 10-12 days\n* Have regular ultrasound monitoring and blood tests to track follicle development\n* Undergo egg retrieval procedure when follicles are mature\n* Have all embryos cultured in the EmbryoScope time-lapse incubator with continuous monitoring\n* Have embryos frozen on Day 5\u002F6 for future transfer\n\nStudy Location:\n\nDepartment of Assisted Reproduction and Andrology, Hanoi Obstetrics and Gynecology Hospital\n\nStudy Duration: January 2026 - June 2028",[72,73,74],"Infertility (IVF Patients)","Embryo Morphokinetics","Progestins Primed Ovarian Stimulation",[76,77,78],"IVF","PPOS","Embryo morphokinetics","2026-02-12",{"date":81,"type":82},"2026-02-13","ACTUAL",{"date":84,"type":82},"2026-01-21",{"date":86,"type":66},"2028-10",{"name":5,"class":6},1]